Search

We’re making progress on standardizing single-use systems – and it could mean a more cost-effective supply chain.

Gene therapy manufacturers will need to focus on upstream filtration to minimize the risk of viral infection.

How can manufacturers avoid frustrating and inadvertent changes to the solid forms of APIs?

Lives and livelihoods depend on accelerating large molecule drug production, so biopharma companies must minimize defects and contamination.

Catalent combines its formulation and bioavailability enhancement experience, along with delivery technologies, to support new product launches.

As the world grasps the severity of the ongoing pandemic, we must ask how we can accelerate vaccine development safely.

It is well accepted that vaccine development needs to move faster, but how can companies balance compliance and speed?

How are counterfeiters exploiting the COVID-19 pandemic to make a profit?

Harnessing the potential of microphysiological systems to advance drug discovery.

It is essential that drug development incorporates the patient view.